Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danny Vesprini

Showing results (111-120 of 144) with videos related to

Pageof 15
Sort By:
BMJ Open|May 7, 2026
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trialSian Cooper, Sophie Alexander, Dylan Breitkreutz, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2025
Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate CancerMathijs G Dassen, Alison C Tree, Lisa Wiersema, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Practical Radiation Oncology|September 19, 2020
A Feasibility Study of Mepitel Film for the Prevention of Breast Radiation Dermatitis in a Canadian CenterCaitlin Yee, Emily Lam, Francois Gallant, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 8, 2026
Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility studySian Cooper, Sophie Alexander, Charlotte Cherry, et al.
Breast Cancer Research and Treatment|June 4, 2026
Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitisSarah Bayrakdarian, Caroline Hircock, Henry C Y Wong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
Pageof 15

Showing results (111-120 of 144) with videos related to

Sort By:
Pageof 15
BMJ Open|May 7, 2026
Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trialSian Cooper, Sophie Alexander, Dylan Breitkreutz, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
International Journal of Radiation Oncology, Biology, Physics|November 28, 2025
Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate CancerMathijs G Dassen, Alison C Tree, Lisa Wiersema, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Practical Radiation Oncology|September 19, 2020
A Feasibility Study of Mepitel Film for the Prevention of Breast Radiation Dermatitis in a Canadian CenterCaitlin Yee, Emily Lam, Francois Gallant, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 8, 2026
Acute adverse events in the DESTINATION 1 trial: A prospective prostate SBRT dose de-escalation feasibility studySian Cooper, Sophie Alexander, Charlotte Cherry, et al.
Breast Cancer Research and Treatment|June 4, 2026
Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitisSarah Bayrakdarian, Caroline Hircock, Henry C Y Wong, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2019
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trialsYasir Alayed, Harvey Quon, Patrick Cheung, et al.
European Urology Oncology|February 4, 2025
Two-fraction Versus Five-fraction Stereotactic Body Radiotherapy for Intermediate-risk Prostate Cancer: The TOFFEE Meta-analysis of Individual Patient Data from Four Prospective TrialsCristian Udovicich, Patrick Cheung, William Chu, et al.
Pageof 15